Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer

Abstract Background A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the safety and...

Full description

Bibliographic Details
Main Authors: Daisuke Kotani, Yasutoshi Kuboki, Satoshi Horasawa, Asumi Kaneko, Yoshiaki Nakamura, Akihito Kawazoe, Hideaki Bando, Hiroya Taniguchi, Kohei Shitara, Takashi Kojima, Akihito Tsuji, Takayuki Yoshino
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Cancer
Subjects:
Trifluridine/tipiracil plus bevacizumab
TAS-102
mCRC
Lonsurf
Online Access:https://doi.org/10.1186/s12885-019-6475-6

Internet

https://doi.org/10.1186/s12885-019-6475-6

Similar Items